Further progress on defining highly conserved immunogenic epitopes for a global HIV vaccine: HLA-A3-restricted GAIA vaccine epitopes

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 7, 2012, Pages 987-1000

  De Groot, Anne S ^a,b,c   Levitz, Lauren ^a   Ardito, Matthew T ^a   Skowron, Gail ^d   Mayer, Kenneth H ^e   Buus, Soren ^f   Boyle, Christine M ^a   Martin, William D ^a  

^a EpiVax Inc   (United States)

^b UNIVERSITY OF RHODE ISLAND   (United States)

^c GAIA Vaccine Foundation   (United States)

^d ROGER WILLIAMS MEDICAL CENTER   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Epitope vaccine; GAIA globally relevant HIV vaccine; HLA A3 HIV epitopes; Immunoinformatics; T cell vaccine

Indexed keywords

ANTIRETROVIRUS AGENT; EPITOPE; HLA A3 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

AMINO ACID SEQUENCE; ANTIGEN BINDING; ARTICLE; CLADISTICS; CLINICAL ARTICLE; CYTOTOXIC T LYMPHOCYTE; DRUG DESIGN; GENETIC CONSERVATION; GEOGRAPHY; GLOBAL ALLIANCE TO IMMUNIZE AGAINST AIDS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOGENICITY; IN VITRO STUDY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PREDICTION; SEQUENCE ANALYSIS; UNITED STATES; VACCINATION; VACCINE PRODUCTION; VALIDATION STUDY; BIOLOGY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; METABOLISM; METHODOLOGY; MONONUCLEAR CELL; NUCLEOTIDE SEQUENCE;

AIDS VACCINES; COMPUTATIONAL BIOLOGY; CONSERVED SEQUENCE; EPITOPES, T-LYMPHOCYTE; HIV INFECTIONS; HIV-1; HLA-A3 ANTIGEN; HUMANS; LEUKOCYTES, MONONUCLEAR; RHODE ISLAND;

EID: 84864032169     PISSN: None     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.20528     Document Type: Article

References (52)

1. Global report: UNAIDS report on the global AIDS epidemic 2010. Joint United Nations Programme on HIV/AIDS. Geneva: Issue 2010.
2. Global H. IV/AIDS Response: Epidemic update and health sector progress towards Universal Access Progress Report 2011. World Health Organization Department of HIV/AIDS. Geneva: World Health Organization, 2011.
3. Graham BS. Clinical trials of HIV vaccines. Annu Rev Med 2002; 53:207-21; PMID:11818471; http://dx.doi.org/10.1146/annurev.med.53.082901.104035.
4. Dieffenbach CW, Fauci AS. Thirty years of HIV and AIDS: future challenges and opportunities. Ann Intern Med 2011; 154:766-71; PMID:21628350.
5. Kawashima Y, Pfafferott K, Frater J, Matthews P, Payne R, Addo M, et al. Adaptation of HIV-1 to human leukocyte antigen class I. Nature 2009; 458:641-5; PMID:19242411; http://dx.doi.org/10.1038/nature07746.
6. Rousseau CM, Daniels MG, Carlson JM, Kadie C, Crawford H, Prendergast A, et al. HLA class I-driven evolution of human immunodeficiency virus type 1 subtype c proteome: immune escape and viral load. J Virol 2008; 82:6434-46; PMID:18434400; http://dx.doi.org/10.1128/JVI.02455-07.
7. Fuchs JD, Sobieszczyk ME, Hammer SM, Buchbinder SP. Lessons drawn from recent HIV vaccine efficacy trials. J Acquir Immune Defic Syndr 2010; 55:128-31; PMID:21406982; http://dx.doi.org/10.1097/QAI.0b013e3181fbca02.
8. Munier CM, Andersen CR, Kelleher AD. HIV vaccines: progress to date. Drugs 2011; 71:387-414; PMID:21395355.
9. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al.; MOPHTAVEG Investigators. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:2209-20; PMID:19843557; http://dx.doi.org/10.1056/NEJMoa0908492.
10. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012; 366:1275-86; PMID:22475592; http://dx.doi.org/10.1056/NEJMoa1113425.
11. Hu DJ, Vitek CR, Bartholow B, Mastro TD. Key issues for a potential human immunodeficiency virus vaccine. Clin Infect Dis 2003; 36:638-44; PMID:12594646; http://dx.doi.org/10.1086/367891.
12. Baden LR, Dolin R. The road to an effective HIV vaccine. N Engl J Med 2012; 366:1343-4; PMID:22475599; http://dx.doi.org/10.1056/NEJMe1202492.
13. Shedlock DJ, Shen H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 2003; 300:337-9; PMID:12690201; http://dx.doi.org/10.1126/science.1082305.
14. Heeney JL. Requirement of diverse T-helper responses elicited by HIV vaccines: induction of highly targeted humoral and CTL responses. Expert Rev Vaccines 2004; 3:53-64; PMID:15285705; http://dx.doi.org/10.1586/14760584.3.4. S53.
15. + T cell responses. PLoS One 2011; 6:16921; PMID:21347287; http://dx.doi.org/10.1371/journal.pone. 0016921.
16. Musey L, Hughes J, Schacker T, Shea T, Corey L, McElrath MJ. Cytotoxic-T-cell responses, viral load and disease progression in early human immunodeficiency virus type 1 infection. N Engl J Med 1997; 337:1267-74; PMID:9345075; http://dx.doi.org/10.1056/NEJM199710303371803.
17. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994; 68:4650-5; PMID:8207839.
18. Ferrari G, Korber B, Goonetilleke N, Liu MKP, Turnbull EL, Salazar-Gonzalez JF, et al. Relationship between functional profile of HIV-1 specific CD8 T cells and epitope variability with the selection of escape mutants in acute HIV-1 infection. PLoS Pathog 2011; 7:1001273; PMID:21347345; http://dx.doi.org/10.1371/journal.ppat.1001273.
19. Troyer RM, McNevin J, Liu Y, Zhang SC, Krizan RW, Abraha A, et al. Variable fitness impact of HIV-1 escape mutations to cytotoxic T lymphocyte (CTL) response. PLoS Pathog 2009; 5:1000365; PMID:19343217; http://dx.doi.org/ 10.1371/journal.ppat.1000365.
20. + T cells. J Virol 2009; 83:7641-8; PMID:19458000; http://dx.doi.org/10.1128/JVI.00182-09.
21. Brumme ZL, John M, Carlson JM, Brumme CJ, Chan D, Brockman MA, et al. HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins. PLoS One 2009; 4:6687; PMID:19690614; http://dx.doi.org/10.1371/ journal.pone.0006687.
22. + T cells secreting MIP-1beta but not IFNgamma are associated with nonprogressive HIV-1 infection. AIDS Res Ther 2010; 7:20; PMID:20598119; http://dx.doi.org/10.1186/1742-6405-7-20.
23. + T-cell suppression of siv viremia is not mediated by CTL clearance of productively infected cells. PLoS Pathog 2010; 6:1000748; PMID:20126442; http://dx.doi.org/10.1371/journal.ppat.1000748.
24. + T-cell responses represents a major driving force of human immunodeficiency virus type 1 (HIV-1) sequence diversity and reveals constraints on HIV-1 evolution. J Virol 2005; 79:13239-49; PMID:16227247; http://dx.doi.org/10.1128/JVI.79.21.13239-49.2005.
25. Jesdale BM, Deocampo G, Meisell J, Beall J, Marinello MJ, Chicz RM, et al. Matrix-based prediction of MHC binding peptides: The EpiMatrix algorithm, reagent for HIV research. Vaccines '97. Cold Spring Harbor Press, Cold Spring Harbor, NY 1997.
26. De Groot AS, Rivera DS, McMurry JA, Buus S, Martin W. Identification of immunogenic HLA-B7 "Achilles'Heel" epitopes within highly conserved regions of HIV. Vaccine 2008; 26:305-7; PMID:18083279; http://dx.doi.org/10. 1016/j.vaccine.2007.12.004.
27. Matthews PC, Leslie AJ, Katzourakis A, Crawford H, Payne R, Prendergast A, et al. HLA footprints on human immunodeficiency virus type 1 are associated with interclade polymorphisms and intraclade phylogenetic clustering. J Virol 2009; 83:4605-15; PMID:19244334; http://dx.doi.org/10.1128/JVI.02017-08.
28. Peyerl FW, Bazick HS, Newberg MH, Barouch DH, Sodroski J, Letvin NL. Fitness costs limit viral escape from cytotoxic T lymphocytes at a structurally constrained epitope. J Virol 2004; 78:13901-10; PMID:15564498; http://dx.doi.org/10.1128/JVI.78.24.13901-10.2004.
29. Frahm N, Korber BT, Adams CM, Szinger JJ, Draenert R, Addo MM, et al. Consistent cytotoxic-T-lymphocyte targeting of immunodominant regions in human immunodeficiency virus across multiple ethnicities. J Virol 2004; 78:2187-200; PMID:14963115; http://dx.doi.org/10.1128/JVI.78.5.2187-200.2004.
30. Wang YE, Li B, Carlson JM, Streeck H, Gladden AD, Goodman R, et al. Protective HLA class I alleles that restrict acute-phase CD8+ T-cell responses are associated with viral escape mutations located in highly conserved regions of human immunodeficiency virus type 1. J Virol 2009; 83:1845-55; PMID:19036810; http://dx.doi.org/10.1128/JVI.01061-08.
31. Yang OO, Daar ES, Ng HL, Shih R, Jamieson BD. Increasing CTL targeting of conserved sequences during early HIV-1 infection is correlated to decreasing viremia. AIDS Res Hum Retroviruses 2011; 27:391-8; PMID:21087140; http://dx.doi.org/10.1089/aid.2010.0183.
32. Julg B, Williams KL, Reddy S, Bishop K, Qi Y, Carrington M, et al. Enhanced anti-HIV functional activity associated with Gag-specific CD8 T-cell responses. J Virol 2010; 84:5540-9; PMID:20335261; http://dx.doi.org/10.1128/ JVI.02031-09.
33. Duda A, Lee-Turner L, Fox J, Robinson N, Dustan S, Kaye S, et al.; SPARTAC Trial Investigators. HLA-associated clinical progression correlates with epitope reversion rates in early human immunodeficiency virus infection. J Virol 2009; 83:1228-39; PMID:19019964; http://dx.doi.org/10.1128/JVI.01545-08.
34. Ahlers JD, Belyakov IM. Lessons learned from natural infection: focusing on the design of protective T cell vaccines for HIV/AIDS. Trends Immunol 2010; 31:120-30; PMID:20089450; http://dx.doi.org/10.1016/j.it.2009.12.003.
35. Zhang C, Cornette JL, Berzofsky JA, DeLisi C. The organization of human leucocyte antigen class I epitopes in HIV genome products: implications for HIV evolution and vaccine design. Vaccine 1997; 15:1291-302; PMID:9302734; http://dx.doi.org/10.1016/S0264-410X(97)00040-6.
36. Sidney J, Peters B, Frahm N, Brander C, Sette A. HLA class I supertypes: a revised and updated classification. BMC Immunol 2008; 9:1-15; PMID:18211710; http://dx.doi.org/10.1186/1471-2172-9-1.
37. Koita OA, Dabitao D, Mahamadou I, Tall M, Dao S, Tounkara A, et al. Confirmation of immunogenic consensus sequence HIV-1 T-cell epitopes in Bamako, Mali and Providence, Rhode Island. Hum Vaccin 2006; 2:119-28; PMID:17012903.
38. Gonzalez-Galarza FF, Christmas S, Middleton D, Jones AR. Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations. Nucleic Acids Res 2011; 39:913-9; PMID:21062830; http://dx.doi.org/10.1093/nar/gkq1128.
39. De Groot AS, Ardito M, McClaine EM, Moise L, Martin WD. Immunoinformatic comparison of T-cell epitopes contained in novel swine-origin influenza A (H1N1) virus with epitopes in 2008-2009 conventional influenza vaccine. Vaccine 2009; 27:5740-7; PMID:19660593; http://dx.doi.org/10.1016/j.vaccine.2009.07.040.
40. Zhao S, Zhai S, Zhuang Y, Wang S, Huang D, Kang W, et al. Inter-clade cross-reactivity of HIV-1-specific T cell responses in human immunodeficiency virus type 1 infection in China. Curr HIV Res 2007; 5:251-9; PMID:17346138; http://dx.doi.org/10.2174/157016207780076995.
41. Dadaglio G, Leroux A, Langlade-Demoyen P, Bahraoui EM, Traincard F, Fisher R, et al. Epitope recognition of conserved HIV envelope sequences by human cytotoxic T lymphocytes. J Immunol 1991; 147:2302-9; PMID:1717555.
42. Lieberman J, Fabry JA, Shankar P, Beckett L, Skolnik PR. Ex vivo expansion of HIV type 1-specific cytolytic T cells from HIV type 1-seropositive subjects. AIDS Res Hum Retroviruses 1995; 11:257-71; PMID:7742040; http://dx.doi.org/10.1089/aid.1995.11.257.
43. Johnson RP, Hammond SA, Trocha A, Siliciano RF, Walker BD. Induction of a major histocompatibility complex class I-restricted cytotoxic T-lymphocyte response to a highly conserved region of human immunodeficiency virus type 1 (HIV-1) gp120 in seronegative humans immunized with a candidate HIV-1 vaccine. J Virol 1994; 68:3145-53; PMID:7908700.
44. Sriwanthana B, Hodge T, Mastro TD, Dezzutti CS, Bond K, Stephens HA, et al. HIV-specific cytotoxic T lymphocytes, HLA-A11 and chemokine-related factors may act synergistically to determine HIV resistance in CCR5 delta32-negative female sex workers in Chiang Rai, northern Thailand. AIDS Res Hum Retroviruses 2001; 17:719-34; PMID:11429112; http://dx.doi.org/10.1089/088922201750236997.
45. Bond KB, Sriwanthana B, Hodge TW, De Groot AS, Mastro TD, Young NL, et al. An HLA-directed molecular and bioinformatics approach identifies new HLAA11 HIV-1 subtype E cytotoxic T lymphocyte epitopes in HIV-1-infected Thais. AIDS Res Hum Retroviruses 2001; 17:703-17; PMID:11429111; http://dx.doi.org/10.1089/ 088922201750236988.
46. + T cells: cytotoxic T-lymphocyte epitopes and precursor frequencies. AIDS 1993; 7:781-6; PMID:7689847; http://dx.doi.org/10.1097/ 00002030-199306000-00004.
47. Gong X, Gui X, Zhang Y, Tien P. Screening for CD8 cytotoxic T lymphocytes specific for Gag of human immunodeficiency virus type 1 subtype B' Henan isolate from China and identification of novel epitopes restricted by the HLA-A2 and HLA-A11 alleles. J Gen Virol 2006; 87:151-8; PMID:16361427; http://dx.doi.org/10.1099/vir.0.81335-0.
48. Harari A, Cellerai C, Enders FB, Köstler J, Codarri L, Tapia G, et al. Skewed association of polyfunctional antigen-specific CD8 T cell populations with HLA-B genotype. Proc Natl Acad Sci USA 2007; 104:16233-8; PMID:17911249; http://dx.doi.org/10.1073/pnas.0707570104.
49. Frahm N, Yusim K, Suscovich TJ, Adams S, Sidney J, Hraber P, et al. Extensive HLA class I allele promiscuity among viral CTL epitopes. Eur J Immunol 2007; 37:2419-33; PMID:17705138; http://dx.doi. org/10.1002/eji.200737365.
50. Novitsky V, Rybak N, McLane MF, Gilbert P, Chigwedere P, Klein I, et al. Identification of human immunodeficiency virus type 1 subtype C Gag-, Tat-, Rev- and Nef-specific elispot-based cytotoxic T-lymphocyte responses for AIDS vaccine design. J Virol 2001; 75:9210-28; PMID:11533184; http://dx.doi.org/10. 1128/JVI.75.19.9210-28.2001.
51. Dorrell L, O'Callaghan CA, Britton W, Hambleton S, McMichael A, Smith GL, et al. Recombinant modified vaccinia virus Ankara efficiently restimulates human cytotoxic T lymphocytes in vitro. Vaccine 2000; 19:327-36; PMID:10930688; http://dx.doi.org/10.1016/S0264-410X(00)00135-3.
52. Goulder PJ, Sewell AK, Lalloo DG, Price DA, Whelan JA, Evans J, et al. Patterns of immunodominance in HIV-1-specific cytotoxic T lymphocyte responses in two human histocompatibility leukocyte antigens (HLA)-identical siblings with HLA-A*0201 are influenced by epitope mutation. J Exp Med 1997; 185:1423-33; PMID:9126923; http://dx.doi.org/10.1084/jem.185.8.1423.